Demand for faster and more efficient ways to deliver new protein drug candidates is ever-growing as the global market for biopharmaceutical products continuously expands. Moreover, the way early screening for process optimization and clone selection is conducted in the cell line development (CLD) space has been transformed by technological advances in early CLD workflows.
Sartorius’ Ambr® 15 bioreactor platform is a prominent technology in the cell culture space that shifted the processing bottleneck from the upstream portion of CLD and screening to the downstream steps of product processing. To mitigate this bottleneck, a novel downstream processing system was developed that aims to transform the way clarification and/or purification of cell culture samples is performed for downstream analysis.
Evaluate the performance of this system in a monoclonal antibody (mAb) production process.